FBRX · As filed with the SEC
Forte Biosciences income statement, by quarter
The statement as Forte Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) · USD
| USD | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | 22,186,000 | 20,320,000 | — | 15,050,000 |
| Research and development - related party | 150,000 | 150,000 | — | 150,000 |
| General and administrative | 2,267,000 | 1,969,000 | — | 3,183,000 |
| Total operating expenses | 24,603,000 | 22,439,000 | — | 18,383,000 |
| Loss from operations | (24,603,000) | (22,439,000) | — | (18,383,000) |
| Other income, net | 1,465,000 | 676,000 | — | 701,000 |
| Net loss before taxes | (23,138,000) | (21,763,000) | — | — |
| Income tax expense | (193,000) | (373,000) | — | — |
| Net loss | (23,331,000) | (22,136,000) | — | (17,682,000) |
| Net loss per share - basic | (0.97) | (1.24) | — | (0.99) |
| Net loss per share - diluted | (0.97) | (1.24) | — | (0.99) |
| Weighted average shares and pre-funded warrants outstanding, basic | 23,787,713 | 17,837,406 | — | 17,793,907 |
| Weighted average shares and pre-funded warrants outstanding, diluted | 23,787,713 | 17,837,406 | — | 17,793,907 |
| Comprehensive Loss: | ||||
| Net loss | (23,331,000) | (22,136,000) | — | (17,682,000) |
| Unrealized loss on available-for-sale securities, net | (50,000) | (7,000) | — | (6,000) |
| Comprehensive loss | (23,381,000) | (22,143,000) | — | (17,688,000) |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.